The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen

Clinical Infectious Diseases

Volumn 46, Issue 10, 2008, Pages 1617-1623

  Waters, Laura ^a   Mandalia, Sundhiya ^a   Randell, Paul ^a   Wildfire, Adrian ^a   Gazzard, Brian ^a   Moyle, Graeme ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; STRAIN DIFFERENCE; TREATMENT RESPONSE; VIRUS LOAD; VIRUS STRAIN; CLASSIFICATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RECEPTORS, CCR5; RECEPTORS, CXCR4; TREATMENT OUTCOME; VIRAL LOAD;

EID: 43249097018     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587660     Document Type: Article

References (24)

1. Briggs DR, Tuttle DL, Sleasman JW, Goodenow MM. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 2000; 14:2937-9.
2. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophagetropic HIV-1. Science 1996; 272:1955-8.
3. Blanpain C, Libert F, Vassart G, Parmentier M. CCR5 and HIV infection. Receptors Channels 2002; 8:19-31.
4. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866-72.
5. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of X4-using HIV-1 in a large population of ARV-naive individuals. J Infect Dis 2005; 192:466-74.
6. Demarest J, Bonny T, Vavro C, et al. HIV-1 co-receptor tropism in treatment naive and experienced subjects [abstract H-1136]. In: Program and abstracts of the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004.
7. Whitcomb JM, Huang W, Fransen S, et al. Analysis of baseline ENF (T20) susceptibility and co-receptor tropism in two phase-III study populations [abstract 557]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston, MA). 2003.
8. Hunt P, Martin J, Bates M, et al. X4-tropic viruses are common among ARV treated patients with detectable viremia and associated with lower treatment-mediated CD4 gains [abstract 43]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver, CO). 2006.
9. Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44:591-5.
10. Philpott S, Ledergerber B, Klimkait T, et al. CXCR4-specific viral load predicts clinical HIV-1 disease progression during HAART [abstract ThAa0201]. In: Program and abstracts of the 16th International AIDS Conference (Toronto, Canada). 2006.
11. Daar ES, Kesler KL, Petropoulos CJ, et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007; 45:643-9.
12. Koot M, van 't Wout AB, Kootstra NA, de Goede RE, Tersmette M, Schuitemaker H. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis 1996; 173:349-54.
13. + cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-8.
14. Ho S, Shek L, Li A, et al. Co-receptor switch in a macaque infected with CCR5 (R5)-tropic simian-human immunodeficiency virus [abstract 71LB]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles, CA). 2007.
15. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-75.
16. Kassaye S, Johnston E, McColgan B, et al. Persistent viremia despite ART drives viral evolution in the pol and env genes of subtype C HIV-1 [abstract 171]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). 2007.
17. Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD. When should antiretroviral therapy for HIV be started? BMJ 2007; 334:76-8.
18. Shepherd J, Jacobson L, Qiao W, et al. Analysis of the timing of CXCR4-tropic HIV emergence in the MACS cohort [abstract TUPE0001]. In: Program and abstracts of the XVI International AIDS Conference (Toronto). 2006.
19. Goetz MB, Leduc R, Kostman JR, et al. Prediction of disease progression by HIV co-receptor tropism (CRT) in persons (P) with untreated chronic HIV infection [abstract H-1027]. In: Program and abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society for Microbiology, 2007.
20. Wooley D, Marathe J. Primary human eosinophils are highly susceptible to productive infection by X4 HIV-1 [abstract 167]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. 2007.
21. + T cells by HIV-1 [abstract 182]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. 2007.
22. Nelson M, Fätkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results [abstract 104aLB]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. 2007.
23. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada [abstract 104bLB]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. 2007.
24. Hunt P, Huang W, Coakley E, et al. Longitudinal evaluation of viral co-receptor tropism switches among HIV-infected patients with drugresistant viremia [abstract 619]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. 2007.